Literature DB >> 23096432

Intratumoral estrogen concentration and expression of estrogen-induced genes in male breast carcinoma: comparison with female breast carcinoma.

Kiyoshi Takagi1, Takuya Moriya, Masafumi Kurosumi, Kimako Oka, Yasuhiro Miki, Akiko Ebata, Takashi Toshima, Shoji Tsunekawa, Hiroyuki Takei, Hisashi Hirakawa, Takanori Ishida, Shin-Ichi Hayashi, Junichi Kurebayashi, Hironobu Sasano, Takashi Suzuki.   

Abstract

It is speculated that estrogens play important roles in the male breast carcinoma (MBC) as well as the female breast carcinoma (FBC). However, estrogen concentrations or molecular features of estrogen actions have not been reported in MBC, and biological significance of estrogens remains largely unclear in MBC. Therefore, we examined intratumoral estrogen concentrations, estrogen receptor (ER) α/ERβ status, and expression profiles of estrogen-induced genes in MBC tissues, and compared these with FBC. 17β-Estradiol concentration in MBC (n = 4) was significantly (14-fold) higher than that in non-neoplastic male breast (n = 3) and tended to be higher than that in FBC (n = 7). Results of microarray analysis clearly demonstrated that expression profiles of the two gene lists, which were previously reported as estrogen-induced genes in MCF-7 breast carcinoma cell line, were markedly different between MBC and FBC. In the immunohistochemistry, MBC tissues were frequently positive for aromatase (63 %) and 17β-hydroxysteroid dehydrogenase type 1 (67 %), but not for steroid sulfatase (6.7 %). A great majority (77 %) of MBC showed positive for both ERα and ERβ, and its frequency was significantly higher than FBC cases. These results suggest that estradiol is locally produced in MBC tissue by aromatase. Different expression profiles of the estrogen-induced genes may associate with different estrogen functions in MBC from FBC, which may be partly due to their ERα/ERβ status.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23096432     DOI: 10.1007/s12672-012-0126-6

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  51 in total

1.  Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.

Authors:  Trevor M Penning; Stephan Steckelbroeck; David R Bauman; Meredith W Miller; Yi Jin; Donna M Peehl; Kar-Ming Fung; Hseuh-Kung Lin
Journal:  Mol Cell Endocrinol       Date:  2006-01-18       Impact factor: 4.102

2.  Nucleobindin 2 in human breast carcinoma as a potent prognostic factor.

Authors:  Shiho Suzuki; Kiyoshi Takagi; Yasuhiro Miki; Yoshiaki Onodera; Jun-Ichi Akahira; Akiko Ebata; Takanori Ishida; Mika Watanabe; Hironobu Sasano; Takashi Suzuki
Journal:  Cancer Sci       Date:  2011-11-17       Impact factor: 6.716

3.  Multidisciplinary meeting on male breast cancer: summary and research recommendations.

Authors:  Larissa A Korde; Jo Anne Zujewski; Leah Kamin; Sharon Giordano; Susan Domchek; William F Anderson; John M S Bartlett; Karen Gelmon; Zeina Nahleh; Jonas Bergh; Bruno Cutuli; Giancarlo Pruneri; Worta McCaskill-Stevens; Julie Gralow; Gabriel Hortobagyi; Fatima Cardoso
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

4.  A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences.

Authors:  Abeer M Shaaban; Graham R Ball; Rebecca A Brannan; Gabor Cserni; Anna Di Benedetto; Jo Dent; Laura Fulford; Helen Honarpisheh; Lee Jordan; J Louise Jones; Rani Kanthan; Loaie Maraqa; Maria Litwiniuk; Marcella Mottolese; Steven Pollock; Elena Provenzano; Philip R Quinlan; Georgina Reall; Sami Shousha; Mark Stephens; Eldo T Verghese; Rosemary A Walker; Andrew M Hanby; Valerie Speirs
Journal:  Breast Cancer Res Treat       Date:  2011-11-18       Impact factor: 4.872

Review 5.  MYC in breast tumor progression.

Authors:  Yinghua Chen; Olufunmilayo I Olopade
Journal:  Expert Rev Anticancer Ther       Date:  2008-10       Impact factor: 4.512

6.  The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer.

Authors:  Zuncai Wang; Sonika Dahiya; Heather Provencher; Beth Muir; Erin Carney; Kathryn Coser; Toshi Shioda; Xiao-Jun Ma; Dennis C Sgroi
Journal:  Clin Cancer Res       Date:  2007-11-01       Impact factor: 12.531

7.  Breast carcinoma in men: a population-based study.

Authors:  Sharon H Giordano; Deborah S Cohen; Aman U Buzdar; George Perkins; Gabriel N Hortobagyi
Journal:  Cancer       Date:  2004-07-01       Impact factor: 6.860

8.  Her-2/neu gene amplification and protein expression in primary male breast cancer.

Authors:  Christian Rudlowski; Nicolaus Friedrichs; Andree Faridi; Lazlo Füzesi; Roland Moll; Gunther Bastert; Werner Rath; Reinhard Büttner
Journal:  Breast Cancer Res Treat       Date:  2004-04       Impact factor: 4.872

9.  Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues.

Authors:  Yutaka Yamamoto; Jun-Ichi Yamashita; Masakazu Toi; Mariko Muta; Shigenori Nagai; Nobuo Hanai; Akiko Furuya; Yoshio Osawa; Shigehira Saji; Michio Ogawa
Journal:  Oncol Rep       Date:  2003 Jul-Aug       Impact factor: 3.906

Review 10.  The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application.

Authors:  S-I Hayashi; H Eguchi; K Tanimoto; T Yoshida; Y Omoto; A Inoue; N Yoshida; Y Yamaguchi
Journal:  Endocr Relat Cancer       Date:  2003-06       Impact factor: 5.678

View more
  6 in total

1.  Obesity and male breast cancer: provocative parallels?

Authors:  Matthew P Humphries; V Craig Jordan; Valerie Speirs
Journal:  BMC Med       Date:  2015-06-04       Impact factor: 8.775

Review 2.  Phase two steroid metabolism and its roles in breast and prostate cancer patients.

Authors:  Keely M McNamara; Yasuhiro Nakamura; Yasuhiro Miki; Hironobu Sasano
Journal:  Front Endocrinol (Lausanne)       Date:  2013-09-04       Impact factor: 5.555

3.  Immunolocalization of corticotropin-releasing hormone (CRH) and its receptors (CRHR1 and CRHR2) in human endometrial carcinoma: CRHR1 as a potent prognostic factor.

Authors:  Naoko Sato; Kiyoshi Takagi; Takashi Suzuki; Yasuhiro Miki; Sota Tanaka; Satoru Nagase; Hitoshi Warita; Shin Fukudo; Fumiko Sato; Hironobu Sasano; Kiyoshi Ito
Journal:  Int J Gynecol Cancer       Date:  2014-11       Impact factor: 3.437

4.  HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes.

Authors:  Anna Di Benedetto; Marcella Mottolese; Francesca Sperati; Cristiana Ercolani; Luigi Di Lauro; Laura Pizzuti; Patrizia Vici; Irene Terrenato; Abeer M Shaaban; Sreekumar Sundara-Rajan; Matthew P Humphries; Maddalena Barba; Valerie Speirs; Ruggero De Maria; Marcello Maugeri-Saccà
Journal:  Sci Rep       Date:  2016-10-07       Impact factor: 4.379

Review 5.  The Regulation of Steroid Action by Sulfation and Desulfation.

Authors:  Jonathan W Mueller; Lorna C Gilligan; Jan Idkowiak; Wiebke Arlt; Paul A Foster
Journal:  Endocr Rev       Date:  2015-07-27       Impact factor: 19.871

6.  Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment.

Authors:  K Takagi; T Ishida; Y Miki; H Hirakawa; Y Kakugawa; G Amano; A Ebata; N Mori; Y Nakamura; M Watanabe; M Amari; N Ohuchi; H Sasano; T Suzuki
Journal:  Br J Cancer       Date:  2013-06-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.